

Subject:	Research and Development Update Q2 2020/21	Date: 1st October 2020		
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	Elizabeth Gemmill, Research and Innovation Director			
Presented By:	Elizabeth Gemmill Research and Innovation Director			
Purpose				
To present the Research and Innovation Quarterly Report 2020/2021		Decision		
Update and assurance on performance KPI's and financial position		Approval		
Update on Urgent Public Health (UPH) COVID-19 research portfolio at SFH		Assurance		X
Strategic Objectives				
To provide outstanding care	To promote and support health and wellbeing	To maximise the potential of our workforce	To continuously learn and improve	To achieve better value
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Confirmed £732,459.50 EMCRN budget, a 2.7% increase on 19/20, (excl NHS pay award) Commercial income for re-investment £29,620.87, a 75% decrease on 19/20 income at Q2. Due to suspension of commercial activity in response to the pandemic 			
Patient Impact	<ul style="list-style-type: none"> 1691 participants recruited in to research studies at Q2, 1535 in to UPH studies 			
Staff Impact	<ul style="list-style-type: none"> Focus on supporting Clinical Divisions to deliver priority targets for research COVID-19 research for staff participation secured 			
Services				
Reputational	<ul style="list-style-type: none"> Retain have a strong reputation for research delivery across the region exemplar in financial probity 2nd highest recruiting Trust to UPH studies against similar sized Trusts in England 4th highest recruiting Trust to UPH studies across the East Midlands 			
Committees/groups where this item has been presented before				
QA Cabinet in modified format				
Executive Summary				
Performance Metrics				
<ol style="list-style-type: none"> 1691 participants recruited in to research studies at Q2, 1535 in to UPH studies 74 studies on the SFH portfolio Annual budget from EMCRN £732,459.50, 2.7% increase on 19/20 				

3. Commercial income at Q2 £29,620.87, 72% less than Q2 19/20

R&I RESTART Programme

- 64 trials suspended during pandemic, 27 studies reopened (42%) 36 remain suspended
- R&I have employed a RAG rating system to manage suspension and restart
- R&I are following the NIHR National Restart Framework

COVID-19 research studies taking place at SFH

- 9 studies open
- Combination of interventional drug trials, sample and data collection and observational studies
- Studies available for both staff and patients to participate in

Research Priorities

- Secure and deliver suitable UPH studies to maximise opportunities for our community
- Work with and support Clinical Divisions to meet priority objective related to research
- Increase partnership working with HEI's by developing a partnership with Nottingham Trent University
- Work closely with the transformation team to develop a mechanism to capture and cultivate new and innovative ideas with a focus on commercialisation and intellectual property

Response to Trust Board questions related to research opportunities

- How many potential participants decline to take part in research?
- What percentage of SFH patients are participating in research?